Sanofi India Limited (SIL) reported steady growth in Q4 2024, with revenue growing 9.7% year-on-year (YoY) to ₹514.9 crore, compared to ₹469.2 crore in the same quarter last year.
EBITDA grew 18.8% year-on-year to ₹118.3 crore, from ₹99.6 crore. Operating margins also improved to 23%, compared to 21.2% in Q4 2023.
However, the company’s net profit declined 33.7% to ₹91.3 crore, from ₹137.7 crore a year ago.
On the bright side, the board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholders’ approval at the forthcoming Annual General Meeting.
Sanofi India’s recent partnerships in the cardiovascular (CV) and central nervous system (CNS) segments have set the stage for expansion, with the company saying their execution has met expectations.
The company continues to pursue its ‘India for India’ strategy, which focuses on go-to-market initiatives, operational efficiency and innovation.
Sanofi India Managing Director Rodolfo Herroz said, “In a year of significant transformation, we successfully launched our best-in-class diabetes medicine Soliqua® for the premix segment, which has received encouraging acceptance.” He added that partnerships in the CNS and CV segments are progressing well, with promising initial results.
Sanofi, which has been present in India for nearly seven decades, is focused on increasing the availability of its products while improving efficiency in its operations.
